https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-05-14 / Cancer Chemother. Pharmacol. 2013 Jul;72(1):139-46
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-05-14 / Cancer Chemother. Pharmacol. 2013 Jul;72(1):139-462013-05-14 00:00:002013-05-14 00:00:00Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-03-13 / PLoS One 2013;8(3):e59051
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-03-13 / PLoS One 2013;8(3):e590512013-03-13 00:00:002013-03-13 00:00:00A low selenium level is associated with lung and laryngeal cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-10-26 / Nutr Res 2012 Nov;32(11):873-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-10-26 / Nutr Res 2012 Nov;32(11):873-832012-10-26 00:00:002021-06-30 13:46:04Ascorbic acid alleviates toxicity of paclitaxel without interfering with the anticancer efficacy in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-10-09 / PLoS One 2012;7(10):e46644
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-10-09 / PLoS One 2012;7(10):e466442012-10-09 00:00:002012-10-09 00:00:00Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-07-20 / Br J Haematol 2011 Aug;154(4):448-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-07-20 / Br J Haematol 2011 Aug;154(4):448-562011-07-20 00:00:002011-07-20 00:00:00Serum selenium concentration at diagnosis and outcome in patients with haematological malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-08 / Cancer Chemother. Pharmacol. 2011 May;67(5):1157-66
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-08 / Cancer Chemother. Pharmacol. 2011 May;67(5):1157-662010-08-08 00:00:002010-08-08 00:00:00Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-02-03 / Int J Radiat Oncol Biol Phys 2010 Nov;78(3):828-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-02-03 / Int J Radiat Oncol Biol Phys 2010 Nov;78(3):828-352010-02-03 00:00:002010-02-03 00:00:00Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-08-01 / Anticancer Res 2009 Aug;29(8):3465-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-08-01 / Anticancer Res 2009 Aug;29(8):3465-72009-08-01 00:00:002009-08-01 00:00:00Serum and tissue selenium levels in gastric cancer patients and correlation with CEA
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-01 / Acta Oncol 2009;48(3):452-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-01 / Acta Oncol 2009;48(3):452-62009-01-01 00:00:002009-01-01 00:00:00Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-10-01 / Br. J. Nutr. 2007 Oct;98 Suppl 1:S29-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-10-01 / Br. J. Nutr. 2007 Oct;98 Suppl 1:S29-352007-10-01 00:00:002007-10-01 00:00:00Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses
